Pfizer has partnered with Triana Biomedicines to explore the development of molecular glue degraders, with a focus on oncology applications. This collaboration involves a significant investment from Pfizer and aims to identify promising candidates for cancer treatment. Pfizer will have the exclusive option to license successful candidates identified by Triana, which will enhance its oncology portfolio.
Pfizer has expanded its board of directors with the appointment of Tim Buckley, which could influence the company's strategic direction.
Jazz Pharmaceuticals has reported positive results from a Phase 3 clinical trial involving its drug Zepzelca for the treatment of small cell lung cancer. The combination therapy of Zepzelca and Tecentriq outperformed Tecentriq alone in terms of overall survival and progression-free survival. Jazz Pharmaceuticals plans to seek expanded approval for Zepzelca from the FDA.
MeiraGTx has reported promising results from a small clinical trial for an experimental treatment for Parkinson's disease. The therapy was found to be safe and well-tolerated, with early indications of efficacy. MeiraGTx is optimistic about the trial results and plans to engage with regulatory authorities for further discussions.
Akeso has raised $250 million through a private stock offering to fund international trials for its antibody drugs targeting cancer and autoimmune diseases. The company recently disclosed positive data from a Phase 3 trial, where its drug outperformed a leading immunotherapy. Akeso is well-positioned to advance its clinical programs and expand its presence in the antibody therapy landscape.
Inventiva has appointed Mark Pruzanski as its new chairman and secured approximately $100 million in funding. The funding will be used to complete a Phase 3 trial of its experimental medicine, lanifibranor. This leadership change and financial backing will support Inventiva's clinical trials and strategic direction in the biotechnology industry.